Oncotarget

Reviews:

Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer

Junli Deng, Li Wang, Hongmin Chen, Jingli Hao, Jie Ni, Lei Chang, Wei Duan, Peter Graham and Yong Li _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:55771-55788. https://doi.org/10.18632/oncotarget.9908

Metrics: PDF 2658 views  |   HTML 5052 views  |   ?  


Abstract

Junli Deng1,2,3,4, Li Wang3,4, Hongmin Chen3,4, Jingli Hao1,2, Jie Ni1,2, Lei Chang1,2, Wei Duan5, Peter Graham1,2 and Yong Li1,2

1 Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia

2 St George and Sutherland Clinical School, University of New South Wales (UNSW), Kensington, NSW, Australia

3 Department of Gynecological Oncology, Henan Cancer Hospital, Zhengzhou, Henan, China

4 Zhengzhou University, Zhengzhou, Henan, China

5 School of Medicine, Deakin University, Waurn Ponds, Victoria, Australia

Correspondence to:

Yong Li, email:

Keywords: ovarian cancer, EMT, CSC, chemoresistance, therapy

Received: February 11, 2016 Accepted: May 30, 2016 Published: June 09, 2016

Abstract

Chemoresistance is the main challenge for the recurrent ovarian cancer therapy and responsible for treatment failure and unfavorable clinical outcome. Understanding mechanisms of chemoresistance in ovarian cancer would help to predict disease progression, develop new therapies and personalize systemic therapy. In the last decade, accumulating evidence demonstrates that epithelial-mesenchymal transition and cancer stem cells play important roles in ovarian cancer chemoresistance and metastasis. Treatment of epithelial-mesenchymal transition and cancer stem cells holds promise for improving current ovarian cancer therapies and prolonging the survival of recurrent ovarian cancer patients in the future. In this review, we focus on the role of epithelial-mesenchymal transition and cancer stem cells in ovarian cancer chemoresistance and explore the therapeutic implications for developing epithelial-mesenchymal transition and cancer stem cells associated therapies for future ovarian cancer treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9908